Literature DB >> 26893848

Metabolism of arachidonic acid by the cytochrome P450 enzyme in patients with chronic Keshan disease and dilated cardiomyopathy.

Bing Zhou1, Shulan He2, X I Wang1, Xiaolong Zhen3, Xiaohui Su1, Wuhong Tan1.   

Abstract

Keshan disease (KD) is an endemic cardiomyopathy. The etiology of KD is selenium deficiency; however, it is not the only one and there is no effective approach to preventing and curing this disease. The aim of the present study was to explore the differences in the role of arachidonic acid (AA) by the cytochrome P450 enzyme between chronic KD (CKD), dilated cardiomyopathy (DCM) and control patients. Reverse transcription-quantitative polymerase chain reaction was used to detect the CYP1A1 and CYP2C19 gene expression levels in 6 CKD patients, 6 DCM and 6 healthy controls. An enzyme-linked immunosorbent assay kit was applied to detect serum protein expression of CYP1A1 and CYP2C19, AA and epoxyeicosatrienoic acids (EETs), and 20-hydroxyeicosatetraenoic acids (20-HETE) in 67 CKD patients, 28 DCM, and 58 controls. The present results showed that the expression levels of CYP1A1 and CYP2C19 genes were significantly upregulated compared with the control group (P<0.01). The expression level of the CYP1A1 protein in the CKD (49.55±35.11 pg/ml) and DCM (46.68 ±13.01 pg/ml) groups were enhanced compared with the control group (44.33±16.76 pg/ml) (P<0.01). The production of the CYP2C19 protein in the CKD (57.52±28.22 pg/ml) and DCM (56.36±11.26 pg/ml) groups was enhanced compared with the control group (51.43±10.76 pg/ml). The concentrations of AA in the CKD (126.27±47.91 ng/ml) and DCM (133.24±58.67 ng/ml) groups were also significantly increased compared to the control (78.16±23.90 ng/ml) (P<0.001). The concentration of 20-HETE in the CKD (198.34±17.22 ng/ml) and DCM (194.46±20.35 ng/ml) groups were also significantly increased compared to the control (130.10±16.10 ng/ml) (P<0.001). The only difference between CKD and DCM was for the expression of the CYP1A1 gene and protein. The maximum concentration of EETs was in the control group (44.37±6.14 pg/ml), and the other two groups were lower than the control group (P<0.001). These findings indicated that AA-derived CYP450 metabolites may have a critical role in the pathogenesis of KD and DCM. Upregulation of the CYP2C19 gene and frequent protein expression may be a protective compensation reaction, while CYP1A1 may aggravate myocardial injury.

Entities:  

Keywords:  20-hydroxyeicosatetraenoic acids; Keshan disease; arachidonic acid; dilated cardiomyopathy; epoxyeicosatrienoic acids

Year:  2015        PMID: 26893848      PMCID: PMC4734242          DOI: 10.3892/br.2015.563

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  21 in total

Review 1.  Epoxygenase pathways of arachidonic acid metabolism.

Authors:  D C Zeldin
Journal:  J Biol Chem       Date:  2001-07-12       Impact factor: 5.157

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Mitochondrial-related gene expression profiles suggest an important role of PGC-1alpha in the compensatory mechanism of endemic dilated cardiomyopathy.

Authors:  Shu-Lan He; Wu-Hong Tan; Zeng-Tie Zhang; Feng Zhang; Cheng-Juan Qu; Yan-Xia Lei; Yan-He Zhu; Han-Jie Yu; You-Zhang Xiang; Xiong Guo
Journal:  Exp Cell Res       Date:  2013-08-13       Impact factor: 3.905

Review 4.  The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.

Authors:  Xizhen Xu; Xin A Zhang; Dao Wen Wang
Journal:  Adv Drug Deliv Rev       Date:  2011-04-06       Impact factor: 15.470

Review 5.  Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury.

Authors:  John M Seubert; Darryl C Zeldin; Kasem Nithipatikom; Garrett J Gross
Journal:  Prostaglandins Other Lipid Mediat       Date:  2006-07-10       Impact factor: 3.072

6.  Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel.

Authors:  Eric R Gross; Kasem Nithipatikom; Anna K Hsu; Jason N Peart; John R Falck; William B Campbell; Garrett J Gross
Journal:  J Mol Cell Cardiol       Date:  2004-12       Impact factor: 5.000

7.  2,3,7,8-Tetrachlorodibenzo-p-dioxin and beta-naphthoflavone induce cellular hypertrophy in H9c2 cells by an aryl hydrocarbon receptor-dependant mechanism.

Authors:  Beshay N M Zordoky; Ayman O S El-Kadi
Journal:  Toxicol In Vitro       Date:  2009-12-05       Impact factor: 3.500

8.  Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes.

Authors:  Judy L Raucy; Lisa Mueller; Kui Duan; Scott W Allen; Stephen Strom; Jerome M Lasker
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

9.  Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure.

Authors:  Juey-Jen Hwang; Paul D Allen; George C Tseng; Ching-Wan Lam; Lameh Fananapazir; Victor J Dzau; Choong-Chin Liew
Journal:  Physiol Genomics       Date:  2002-07-12       Impact factor: 3.107

10.  Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats.

Authors:  Beshay N M Zordoky; Mona E Aboutabl; Ayman O S El-Kadi
Journal:  Drug Metab Dispos       Date:  2008-08-25       Impact factor: 3.922

View more
  3 in total

1.  Comparison and Analysis on the Existing Single-Herbal Strategies against Viral Myocarditis.

Authors:  Yu Cao; Yang Liu; Tian Zhang; Jing Pan; Wei Lei; Boli Zhang
Journal:  Genet Res (Camb)       Date:  2021-08-07       Impact factor: 1.588

2.  Preliminary quantitative proteomics analysis in chronic and latent Keshan disease by iTRAQ labeling approach.

Authors:  Yuxiao Sun; Chuanyu Gao; Xianqing Wang; Yuhao Liu
Journal:  Oncotarget       Date:  2017-11-11

3.  Echinocystic acid ameliorates hyperhomocysteinemia-induced vascular endothelial cell injury through regulating NF-κB and CYP1A1.

Authors:  Chuan-Feng Huang; Wei-Na Wang; Cheng-Cao Sun; Yu-Qing Wang; Ling Li; Yin Li; De-Jia Li
Journal:  Exp Ther Med       Date:  2017-09-01       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.